Genmab — Juni 2024
-
Minhua Chu
@chuminhua432
$JNJ announced that its bispecific antibody targeting BCMA/CD3, Tecvayli (teclistamab), has been approved by #China NMPA for the 4th line treatment RRMM in adult patients who have previously received proteasome inhibitor, immunomodulatory agent, and an anti-CD38 antibody. https://x.com/chuminhua432/status/1805569236472893762 -
@zirium.dk: I mine øjne ikke helt uvigtigt hvis man planlægger at handle (sælge/genkøbe/supplere) ud fra tese om, at juni typisk er en dårlig måned i den forstand, at aktien tager et pænt dyk - fordelagtigt at ramme bund juni.
-
@Spēs: Yes, hvis det er formålet, så har du helt ret. Det kunne faktisk være interessant at lave en oversigt over udsvingene for hver måned, altså den største procentvise stigning og fald i løbet af måneden, beregnet fra prisen ved starten af måneden.
-
@Spēs: Jeg har nu lavet en tabel for juni, der viser slutprisen for maj, slutprisen for juni, samt den laveste og højeste intraday pris i juni, og den procentvise ændring for hver af dem med udgangspunkt i slutprisen for maj: https://www.zirium.dk/static/gmab-stock-analysis-june.html
-
old news -
January 8, 2024
FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer
https://www.onclive.com/view/fda-grants-fast-track-status-to-rinatabart-sesutecan-for-fr--expressing-ovarian-cancer -
Der var en grund til, at JvdW ikke ville høre om aktiesplit - han havde allerede en plan
-
the Acasunlimab combi trial set to Active, not recruiting. Ahmadi mentioned on the last call that hey had suffiicient patients to proceed with Ph3 https://www.clinicaltrials.gov/study/NCT05117242?tab=history&a=27&b=28#version-content-panel
-
EPKINLY
(epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) https://ir.genmab.com/news-releases/news-release-details/epkinlyr-epcoritamab-bysp-approved-us-fda-patients-relapsed-or -
Godmorgen
-
Genmab får godkendt kræftmiddel i endnu en indikation i USA https://proinvestor.com/investornyt/1178225/genmab-far-godkendt-kraeftmiddel-i-endnu-en-indikation-i-usa
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1178227/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Godmorgen
syntes ikke rigtig de der godkendelser gør noget ved kursen den siver stille og roligt dybere og dybere og nu deres aktie tilbagekøb slutter så kan jeg godt frygte at den vil falde markant hvis ikke der kommer virkelig som i virkelig gode nyheder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind